CoChat

Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine

Mullen, Saul A., Carney, Patrick W., Roten, Annie, Ching, Michael, Lightfoot, Paul A., Churilov, Leonid, Nair, Umesh, Li, Melody, Berkovic, Samuel F., Petrou, Steven, Scheffer, Ingrid E. · 2018 · Neurology
Cited by 147

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective To evaluate quinidine as a precision therapy for severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1. Methods A single-center, inpatient, order-randomized, blinded, placebo-controlled, crossover trial of oral quinidine included 6 patients with severe autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) due to KCNT1 mutation. Order was block randomized and blinded. Four-day treatment blocks were used with a 2-day washout between. Dose started at 900 mg over 3 divided doses then, in subsequent participants, was reduced to 600 mg, then 300 mg. Primary outcome was seizure frequency measured on continuous video-EEG in those completing the trial. Results Prolonged QT interval occurred in the first 2 patients at doses of 900 and 600 mg quinidine per day, respectively, despite serum quinidine levels well below the therapeutic range (0.61 and 0.51 μg/mL, reference range 1.3–5.0 μg/mL). Four patients completed treatment with 300 mg/d without adverse events. Patients completing the trial had very frequent seizures (mean 14 per day, SD 7, median 13, interquartile range 10–18). Seizures per day were nonsignificantly increased by quinidine (median 2, 95% confidence interval −1.5 to +5, p = 0.15) and no patient had a 50% seizure reduction. Conclusion Quinidine did not show efficacy in adults and teenagers with ADNFLE. Dose-limiting cardiac side effects were observed even in the presence of low measured serum quinidine levels. Although small, this trial suggests use of quinidine in ADNFLE is likely to be ineffective coupled with considerable cardiac risks. Clinical trials registration Australian Therapeutic Goods Administration Clinical Trial Registry (trial number 2015/0151). Classification of evidence This study provides Class II evidence that for persons with severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1, quinidine does not significantly reduce seizure frequency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000004769

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 147

Metadata

Authors
Mullen, S. A., Carney, P. W., Roten, A., Ching, M., Lightfoot, P. A., Churilov, L., Nair, U., Li, M., Berkovic, S. F., Petrou, S., & Scheffer, I. E.
Venue
Neurology
Published
2018-01-02
Volume
90
Issue
1
Pages
e67-e72
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2775120542
Cited by
147
References
6
FWCI
14.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. https://app.cochat.ai/papers/10.1212/wnl.0000000000004769
The paper
Mullen, S. A., Carney, P. W., Roten, A., Ching, M., Lightfoot, P. A., Churilov, L., Nair, U., Li, M., Berkovic, S. F., Petrou, S., & Scheffer, I. E. (2018). Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. Neurology. https://doi.org/10.1212/wnl.0000000000004769

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.